Page last updated: 2024-12-10
mk 0608
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
7-deaza-2'-C-methyladenosine: an antiviral agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 3011893 |
CHEMBL ID | 236207 |
SCHEMBL ID | 733423 |
MeSH ID | M0535762 |
Synonyms (40)
Synonym |
---|
AKOS015840274 |
7-deaza-2'-c-methyl-adenosine |
(2r,3r,4r,5r)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyl-tetrahydrofuran-3,4-diol |
7h-pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-c-methyl-b-d-ribofuranosyl)- |
beta-2'-c-methyl-7-deaza-adenosine |
CHEMBL236207 |
7-deaza-2'-c-methyladenosine |
443642-29-3 |
(2r,3r,4r,5r)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol |
A7035 |
(2r,3r,4r,5r)-2-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyl-tetrahydrofuran-3,4-diol |
(2r,3r,4r,5r)-2-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyltetrahydrofuran-3,4-diol |
7h-pyrrolo(2,3-d)pyrimidin-4-amine, 7-(2-c-methyl-beta-d-ribofuranosyl)- |
mk 0608 |
mk-0608 |
unii-qrr62j6wef |
qrr62j6wef , |
AKOS015901326 |
7h-pyrrolo(2,3-d)pyrimidin-4-amine, 7-(2-c-methyl-.beta.-d-ribofuranosyl)- |
1001913-41-2 |
SCHEMBL733423 |
IRZRJANZDIOOIF-GAJNKVMBSA-N |
4-amino-7-(2-c-methyl-beta-d-ribofuranosyl)-7h-pyrrolo[2,3-d]pyrimidine |
4-amino-7-(2'-methyl-beta-d-ribofuranosyl)-7h-pyrrolo[2,3-d]pyrimidine |
7-(2'-c-methyl-beta-d-ribofuranosyl)-4-amino-pyrrolo[2,3-d]pyrimidine |
mk-608 |
mfcd14584964 |
BBL103031 |
STL556840 |
7-(2-c-methyl-beta-d-ribofuranosyl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine |
CS-0002510 |
(2r,3r,4r,5r)-2-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyl tetrahydrofuran-3,4-diol |
F12808 |
lamevudine |
Q23309937 |
DTXSID60963208 |
HY-10244 |
h5v , |
AS-82894 |
7-deaza-2'-c-methyl-d-adenosine |
Research Excerpts
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
" 2'-C-Methyladenosine was found to be susceptible to enzymatic conversions by adenosine deaminase and purine nucleoside phosphorylase, and it displayed limited oral bioavailability in the rat." | ( Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication. Ball, RG; Bennett, CF; Bera, S; Bhat, B; Bhat, N; Bosserman, M; Brooks, J; Burlein, C; Carroll, SS; Colwell, LF; Cook, PD; Dande, P; Eldrup, AB; Fay, JF; Flores, OA; Getty, K; LaFemina, RL; Leone, J; MacCoss, M; McMasters, DR; Olsen, DB; Prakash, TP; Prhavc, M; Song, Q; Tomassini, JE; Von Langen, D; Wolanski, B, 2004) | 0.32 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (36)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID438027 | Antiviral activity against Dengue virus by cell based assay | 2009 | Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24 | The medicinal chemistry of dengue fever. |
AID662447 | Cytotoxicity against human HuH7 cells after 24 hrs by MTS assay | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12 | Synthesis and characterization of 2'-C-Me branched C-nucleosides as HCV polymerase inhibitors. |
AID1156121 | Cytotoxicity against human HuH7 cells by MTT assay | 2014 | ACS medicinal chemistry letters, Jun-12, Volume: 5, Issue:6 | Discovery and Synthesis of C-Nucleosides as Potential New Anti-HCV Agents. |
AID1542953 | Antiviral activity against Zika virus MR766 infected in African green monkey Vero E6 cells assessed as reduction in virus yield | 2019 | ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4 | Scaffold Morphing Approach To Expand the Toolbox of Broad-Spectrum Antivirals Blocking Dengue/Zika Replication. |
AID740798 | Cytotoxicity against human HuH7 cells | 2013 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7 | Synthesis and evaluation against hepatitis C virus of 7-deaza analogues of 2'-C-methyl-6-O-methyl guanosine nucleoside and L-Alanine ester phosphoramidates. |
AID662448 | Inhibition of HCV genotype 1b NS5B after 90 mins | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12 | Synthesis and characterization of 2'-C-Me branched C-nucleosides as HCV polymerase inhibitors. |
AID1636906 | Inhibition of DOT1L (unknown origin) at 200 uM using chicken nucleosome as substrate in presence of [3H]SAM incubated for 1 hr by TopCount method | 2016 | Bioorganic & medicinal chemistry letters, 09-15, Volume: 26, Issue:18 | New small molecule inhibitors of histone methyl transferase DOT1L with a nitrile as a non-traditional replacement for heavy halogen atoms. |
AID1206545 | Antiviral activity in HCV 2a JFH1 infected in HUH 7-lunet cells after 3 days by Dual-Glo luciferase assay | 2015 | Journal of medicinal chemistry, May-14, Volume: 58, Issue:9 | Highly Selective Phosphatidylinositol 4-Kinase IIIβ Inhibitors and Structural Insight into Their Mode of Action. |
AID662521 | Prodrug activation in Golden Syrian hamster liver assessed as compound triphosphate form at 20 mg/kg, po after 4 to 24 hrs | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12 | Synthesis and characterization of 2'-C-Me branched C-nucleosides as HCV polymerase inhibitors. |
AID1542955 | Selectivity index, ratio of CC50 for African green monkey Vero B cells to EC50 for Dengue virus type 2 NGC infected in African green monkey Vero B cells | 2019 | ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4 | Scaffold Morphing Approach To Expand the Toolbox of Broad-Spectrum Antivirals Blocking Dengue/Zika Replication. |
AID1638600 | Antiviral activity against West Nile virus | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | DDX3X Helicase Inhibitors as a New Strategy To Fight the West Nile Virus Infection. |
AID1156120 | Antiviral activity against Hepatitis C virus assessed as inhibition of subgenomic replicon RNA replication | 2014 | ACS medicinal chemistry letters, Jun-12, Volume: 5, Issue:6 | Discovery and Synthesis of C-Nucleosides as Potential New Anti-HCV Agents. |
AID672003 | Antiviral activity against Hepatitis C virus genotype 1b infected in human HBI10A cells assessed as inhibition of viral replication in presence of 10% FBS | 2012 | Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15 | Synthesis and antiviral properties of novel 7-heterocyclic substituted 7-deaza-adenine nucleoside inhibitors of Hepatitis C NS5B polymerase. |
AID1542950 | Antiviral activity against Zika virus | 2019 | ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4 | Scaffold Morphing Approach To Expand the Toolbox of Broad-Spectrum Antivirals Blocking Dengue/Zika Replication. |
AID1206546 | Cytotoxicity against human HeLa cells | 2015 | Journal of medicinal chemistry, May-14, Volume: 58, Issue:9 | Highly Selective Phosphatidylinositol 4-Kinase IIIβ Inhibitors and Structural Insight into Their Mode of Action. |
AID1206542 | Anticoxsackie activity in CVB3 strain Nancy infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 4 hrs by XTT assay | 2015 | Journal of medicinal chemistry, May-14, Volume: 58, Issue:9 | Highly Selective Phosphatidylinositol 4-Kinase IIIβ Inhibitors and Structural Insight into Their Mode of Action. |
AID299923 | Antiviral activity against HCV genotype 1b in Huh7 cells assessed as inhibition of viral RNA replication after 72 hrs by ribonuclease protection assay | 2007 | Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15 | Synthesis and HCV inhibitory properties of 9-deaza- and 7,9-dideaza-7-oxa-2'-C-methyladenosine. |
AID1206544 | Antiviral activity in HCV 1b infected in HUH 7-lunet cells after 3 days by Dual-Glo luciferase assay | 2015 | Journal of medicinal chemistry, May-14, Volume: 58, Issue:9 | Highly Selective Phosphatidylinositol 4-Kinase IIIβ Inhibitors and Structural Insight into Their Mode of Action. |
AID740799 | Antiviral activity against Hepatitis C virus assessed as inhibition of viral replication | 2013 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7 | Synthesis and evaluation against hepatitis C virus of 7-deaza analogues of 2'-C-methyl-6-O-methyl guanosine nucleoside and L-Alanine ester phosphoramidates. |
AID245909 | Cytotoxicity against HB-1 cells in an MTS-based assay | 2004 | Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21 | Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication. |
AID246173 | Inhibition of HCV RNA replication in a subgenomic bicistronic replicon assay in HB-1 cells | 2004 | Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21 | Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication. |
AID299922 | Antiviral activity against HCV genotype 1b in Huh7 cells assessed as inhibition of viral RNA replication after 24 hrs by ribonuclease protection assay | 2007 | Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15 | Synthesis and HCV inhibitory properties of 9-deaza- and 7,9-dideaza-7-oxa-2'-C-methyladenosine. |
AID1542949 | Antiviral activity against Dengue virus | 2019 | ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4 | Scaffold Morphing Approach To Expand the Toolbox of Broad-Spectrum Antivirals Blocking Dengue/Zika Replication. |
AID1156129 | Inhibition of N-terminal His6-tagged Hepatitis C virus genotype 1b isolate Con1 NS5B RNA-dependent RNA polymerase activity by plate reader analysis | 2014 | ACS medicinal chemistry letters, Jun-12, Volume: 5, Issue:6 | Discovery and Synthesis of C-Nucleosides as Potential New Anti-HCV Agents. |
AID1542952 | Cytotoxicity in African green monkey Vero B cells assessed as reduction in cell viability by MTS assay | 2019 | ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4 | Scaffold Morphing Approach To Expand the Toolbox of Broad-Spectrum Antivirals Blocking Dengue/Zika Replication. |
AID1070548 | Selectivity ratio of EC50 for HCV harboring NS5B RNA dependent RNA polymerase S282T mutant to EC50 for wild-type HCV | 2014 | Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5 | Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients. |
AID1542956 | Selectivity index, ratio of CC50 for African green monkey Vero E6 cells to EC50 for Zika virus MR766 infected in African green monkey Vero E6 cells | 2019 | ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4 | Scaffold Morphing Approach To Expand the Toolbox of Broad-Spectrum Antivirals Blocking Dengue/Zika Replication. |
AID299924 | Cytotoxicity against Huh7 cells after 24 hrs by MTS assay | 2007 | Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15 | Synthesis and HCV inhibitory properties of 9-deaza- and 7,9-dideaza-7-oxa-2'-C-methyladenosine. |
AID662523 | Prodrug activation in Sprague-Dawley rat liver assessed as compound triphosphate form at 2 mg/kg, po after 4 to 24 hrs | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12 | Synthesis and characterization of 2'-C-Me branched C-nucleosides as HCV polymerase inhibitors. |
AID1156119 | Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH7 cells assessed as inhibition of subgenomic replicon RNA replication after 72 hrs by luciferase reporter assay | 2014 | ACS medicinal chemistry letters, Jun-12, Volume: 5, Issue:6 | Discovery and Synthesis of C-Nucleosides as Potential New Anti-HCV Agents. |
AID1206543 | Antirhinovirus activity in HRVM infected in H1-HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by Cell-Titer Glo viability assay | 2015 | Journal of medicinal chemistry, May-14, Volume: 58, Issue:9 | Highly Selective Phosphatidylinositol 4-Kinase IIIβ Inhibitors and Structural Insight into Their Mode of Action. |
AID1156128 | Inhibition of Hepatitis C virus NS5B RNA-dependent RNA polymerase activity | 2014 | ACS medicinal chemistry letters, Jun-12, Volume: 5, Issue:6 | Discovery and Synthesis of C-Nucleosides as Potential New Anti-HCV Agents. |
AID662449 | Stability of the compound assessed as compound remaining at 10 uM after 60 mins in presence of bovine adenosine deaminase | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12 | Synthesis and characterization of 2'-C-Me branched C-nucleosides as HCV polymerase inhibitors. |
AID1542951 | Antiviral activity against Dengue virus type 2 NGC infected in African green monkey Vero B cells assessed as reduction in virus yield | 2019 | ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4 | Scaffold Morphing Approach To Expand the Toolbox of Broad-Spectrum Antivirals Blocking Dengue/Zika Replication. |
AID1542954 | Cytotoxicity in African green monkey Vero E6 cells assessed as reduction in cell viability by MTS assay | 2019 | ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4 | Scaffold Morphing Approach To Expand the Toolbox of Broad-Spectrum Antivirals Blocking Dengue/Zika Replication. |
AID662446 | Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as cytoprotection after 24 hrs | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12 | Synthesis and characterization of 2'-C-Me branched C-nucleosides as HCV polymerase inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (22)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (22.73) | 29.6817 |
2010's | 16 (72.73) | 24.3611 |
2020's | 1 (4.55) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 17.03
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.03) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (4.55%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 21 (95.45%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |